Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Microscopic polyangiitis


Other Names for this Disease
  • Micropolyangiitis
  • Microscopic polyarteritis
  • MPA
Related Diseases
  • Secondary glomerular disease
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

What is the treatment for microscopic polyangiitis (MPA)?

MPA is treated with medications that suppress the immune system, which can lower an individual's resistance to infections. There are a variety of immune suppressing medications that are used in MPA; however, resources state that a steroid (usually prednisone) and a medication toxic to cells (usually starting with cyclophosphamide) are typically prescribed first.[1] The goal of treatment is to stop all of the organ damage that occurs as a result of MPA.[2]  The duration of treatment with immune suppressing medication varies between individuals, but is typically given for at least one to two years.[2]
Last updated: 2/4/2009

References
  1. Microscopic polyangiitis. The Johns Hopkins Vasculitis Center Web site. 2014; http://www.hopkinsvasculitis.org/types-vasculitis/microscopic-polyangiitis/. Accessed 8/13/2014.
  2. Microscopic Polyangiitis. Cleveland Clinic Web site. November 10, 2010; http://my.clevelandclinic.org/disorders/microscopic_polyangiitis/hic_microscopic_polyangitis.aspx. Accessed 8/13/2014.


GARD Video Tutorial

  • Finding Treatment Information - A video developed by GARD Information Specialists that explains how you can find information about treatment for a rare disease.

    Finding Treatment Information

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Microscopic polyangiitis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Rituximab
Trade Name
(Manufacturer Name)
Rituxan
(Genentech, Inc.)
Indication
The FDA has approved this product to be used in this manner.
For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of pateints with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • Micropolyangiitis
  • Microscopic polyarteritis
  • MPA
Related Diseases
  • Secondary glomerular disease
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.